Norway's Aker BioMarine exploring alternatives for Human Health Ingredient unit

Aker Biomarine ASA

12/02/2026 06:19

Overview

Norway's human health innovator's Q4 revenue missed analyst expectations

Adjusted EBITDA for Q4 missed analyst expectations

Company engaged advisers to explore alternatives for Human Health Ingredient unit

Outlook

Company expects krill oil revenues to grow 15-30% YoY in Q1 2026

Aker BioMarine exploring strategic alternatives for Human Health Ingredient unit

Company adapting to macroeconomic trends and implementing cost measures

Result Drivers

HUMAN HEALTH INGREDIENTS - Segment revenue rose 28% YoY, driven by higher volumes and improved price mix

CONSUMER HEALTH PRODUCTS - Revenue fell 8% YoY due to lower demand growth and pressure in drugstore channels

NEW KRILL OIL CUSTOMER - Large new customer for krill oil fully onboarded with strong initial performance

Key Details

Metric
Beat/Miss
Actual
Consensus Estimate
Q4 Revenue
Miss
$55.20 mln
$57.67 mln (3 Analysts)
Q4 Adjusted EBITDA
Miss
$10.60 mln
$13.33 mln (3 Analysts)

Analyst Coverage

The current average analyst rating on the shares is "hold" and the breakdown of recommendations is 1 "strong buy" or "buy", 2 "hold" and no "sell" or "strong sell"

The average consensus recommendation for the fishing & farming peer group is "buy."

Wall Street's median 12-month price target for Aker Biomarine ASA is NOK95.00, about 1.6% below its February 11 closing price of NOK96.50

The stock recently traded at 43 times the next 12-month earnings vs. a P/E of 40 three months ago

Press Release: ID:nObis17DNa

For questions concerning the data in this report, contact Estimates.Support@lseg.com. For any other questions or feedback, contact reuters.support@thomsonreuters.com.

(This story was created using Reuters automation and AI based on LSEG and company data. It was checked and edited by a Reuters journalist prior to publication.)